Extreme prematurity is associated with an increased risk to develop bronchopulmonary dysplasia (BPD). Severe BPD is associated with a significant long-term burden for the affected infant, families and society. Currently there are limited prevention and treatment options. Regenerative approaches using mesenchymal stromal cells (MSC) are associated with promising benefits in animal experiments. First clinical studies, using MSC in humans, suggest safety. To accelerate the process of bench to bed-side development of MSC-based therapies, a global and collaborative approach is needed that includes all key stakeholders. Results of a workshop that was held during the Pediatric Academic Societies meeting in 2019 are summarized. A roadmap is provided discussing next steps of bringing MSC-based interventions into clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41390-020-0758-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesenchymal Stem Cells Carrying Viral Fusogenic Protein p14 to Treat Solid Tumors by Inducing Cell-Cell Fusion and Immune Activation.
Research (Wash D C)
January 2025
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Chimeric antigen receptor (CAR)-based immune cell therapies attack neighboring cancer cells after receptor recognition but are unable to directly affect distant tumor cells. This limitation may contribute to their inefficiency in treating solid tumors, given the restricted intratumoral infiltration and immunosuppressive tumor microenvironment. Therefore, cell-cell fusion as a cell-killing mechanism might develop a novel cytotherapy aimed at improving the efficacy against solid tumors.
View Article and Find Full Text PDFDevelopment of a novel gene expression panel for the characterization of MSCs for increased biological safety.
J Appl Genet
December 2024
Research and Development Department, Polski Bank Komórek Macierzystych S.A. (FamiCord Group), Warsaw, Poland.
Mesenchymal stromal cells (MSCs) have a wide range of therapeutic applications due to their multipotency, immunomodulatory, and anti-inflammatory properties. Their ability to migrate and recolonize damaged tissues is also remarkable. However, the controversial occurrence of spontaneous tumorigenesis or malignant transformation of MSCs raises concerns about proposed cell-based therapies for patients that researchers must address.
View Article and Find Full Text PDFThe Role of Mitochondrial Homeostasis in Mesenchymal Stem Cell Therapy-Potential Implications in the Treatment of Osteogenesis Imperfecta.
Pharmaceuticals (Basel)
September 2024
College of Stomatology, Chongqing Medical University, Chongqing 401147, China.
Osteogenesis imperfecta (OI) is a hereditary disorder characterized by bones that are fragile and prone to breaking. The efficacy of existing therapies for OI is limited, and they are associated with potentially harmful side effects. OI is primarily due to a mutation of collagen type I and hence impairs bone regeneration.
View Article and Find Full Text PDFMesenchymal Stem Cell-Based Biomimetic Liposome for Targeted Treatment of Rheumatoid Arthritis.
ACS Appl Mater Interfaces
September 2024
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disorder that greatly affects joints and current treatments struggle with effectiveness and safety due to nonspecific drug delivery.
- Researchers developed MSCsome, which are biomimetic liposomes made by fusing mesenchymal stem cell membranes with liposomes, enhancing the ability to deliver drugs specifically to affected joints.
- The MSCsome improved targeting to polarized macrophages, leading to better drug accumulation in the joints, significantly reducing inflammation, and aiding in cartilage protection and repair, offering a new method for treating advanced RA.
The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.
Front Cell Dev Biol
July 2024
Slovenian Institute for Transfusion Medicine, Department for Therapeutic Services, Ljubljana, Slovenia.
Mesenchymal stromal stem cells (MSCs) possess a remarkable potential for numerous clinical applications due to their unique properties including self-renewal, immunomodulation, paracrine actions and multilineage differentiation. However, the translation of MSC-based Advanced Therapy Medicinal Products (ATMPs) into the clinic has frequently met with inconsistent outcomes. One of the suspected reasons for this issue is the inherent and extensive variability that exists among such ATMPs, which makes the interpretation of their clinical efficacy difficult to assess, as well as to compare the results of various studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!